内皮ADAR1缺陷诱导NOCT-IRF7轴在肺高血压中的作用
Chen-Shan Chen Woodcock1,2,3, Giovanni Maroli4,5, Hyunbum Kim6
1Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute (C.C.W., Y.Y.T., Y.T., S.O., R.H., S.J., B.W., Y.A.A., T.V.K., S.Y.C.).
在肺高血压 (PH) 中减少ADAR1RNA编辑导致NOCT表达增加,触发免疫信号和细胞死亡. 针对ADAR1-NOCT通路可能提供新的PH疗法.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 肺部医学 肺部医学
背景情况:
- 肺高血压 (PH) 涉及肺动脉内皮细胞 (PAECs) 的早期亡,但其调节不清楚.
- 作用于RNA 1 (ADAR1) 的腺氨酸脱氨酶是一种参与RNA代谢和亡的RNA编辑酶.
- 特定的ADAR1RNA编辑目标和控制PH中PAEC存活率的机制仍然是未知的.
研究的目的:
- 在肺内皮细胞中定义ADAR1-依赖的RNA编辑功能和点.
- 阐明调节PAEC存活率和PH的病变类型的机制.
主要方法:
- 在人类PAH肺部和小鼠模型中评估了ADAR1和Nocturnin (NOCT) 表达和RNA编辑.
- 在低氧条件下使用的体外PAEC模型和在基因操纵和病毒基因传递的体内PH模型.
主要成果:
- 在人类和小鼠PH肺中,ADAR1表达和全球RNA编辑减少.
- 缺氧降低了PAEC中ADAR1的调节,导致NOCT表达的增加和随后的干扰素信号激活和PAEC的亡.
- 沉默NOCT扭转了这些效应,而强迫NOCT表达模仿了ADAR1敲击.
- 在小鼠中,NOCT的遗传删除减轻了PH,在老鼠中,ADAR1的表达改善了PH.
结论:
- 低氧诱导的ADAR1缺陷可调节NOCT,激活PAEC干扰素信号传递,促进细胞亡,并驱动PH的病原性.
- ADAR1-NOCT轴代表了PH诊断和治疗的潜在治疗目标.
更多相关视频
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hypertension II: Pathophysiology
